THE "I"s HAVE IT: IMMUNEX, ISIS EARLY CLINICAL RESULTS WIN FAVOR ON WALL STREET
Executive Summary
Immunex' Phase I results for interleukin-4 receptor and FLT-3 ligand helped drive the stock up more than 40% in February trading to close up 8-1/8 to 28-1/4